FDA puts experimental gMG therapy cladribine on fast track
Note: This story was updated Nov. 26, 2025, to correct that the cladribine formulation being tested as a potential gMG…
Articles by Marisa Wexler, MS
Rese-cel clinical trial results for myasthenia gravis expected in 2026
Results from an ongoing Phase 1/2 clinical trial testing Cabaletta Bio‘s experimental cell therapy rese-cel (resecabtagene autoleucel) in adults…
Stress, rest, and AI: Patients share daily tips for better quality of life
Facing the daily challenges of myasthenia gravis (MG) requires more than medication: It demands diligent self-management, including careful…
At-home Rystiggo infusion safe; most MG patients prefer self-care
Rystiggo (rozanolixizumab-noli) can be safely self-administered by people with myasthenia gravis (MG), according to data from a Phase…
European panel recommends nipocalimab approval for gMG
A European Medicines Agency (EMA) committee recommended that the agency approve nipocalimab as an add-on treatment for generalized myasthenia…
Registry data back Soliris, Ultomiris as safe, effective for gMG
Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are generally safe and effective for easing symptoms of generalized myasthenia gravis…
Claseprubart shows good safety, signs of effectiveness in gMG trial
Treatment with the experimental injection therapy claseprubart (DNTH103) was well tolerated and appeared to ease symptoms of generalized…
‘FDA-aligned’ trial of KYV-101 for MG likely to start enrolling this year
A new Phase 3 clinical trial testing Kyverna Therapeutics’ cell therapy candidate KYV-101 in people with myasthenia gravis (MG)…
2 genes controlling body’s biological clock are dysregulated in MG
Two genes that help to control the human body’s biological clock are dysregulated in myasthenia gravis (MG) — a…
Gefurulimab found to ease gMG symptoms in global Phase 3 trial
Treatment with gefurulimab, an experimental self-administered injection therapy, outperformed a placebo in easing symptoms of generalized myasthenia gravis…